Price may fall next springThe federal Food and Drug Administration approved Truvada (tenofovir disoproxil fumarate/emtricitabine) for HIV treatment in 2004 and for PrEP in 2012.
Although the TDF component is already off patent, the patent for emtricitabine is not set to expire until next September.Last year, Gilead announced agreement with Teva to give the Israeli company exclusive rights to sell a generic version of Truvada in the United States a year ahead of schedule.
These rights will last for six months, after which other companies may join the market. Generic versions of the combo pill are already available in other countries, sold under names such as Tenof-EM, Tavin-EM, and Ricovir.While the arrival of generics can lead to dramatic.